McKesson Acquires 80% Stake in PRISM Vision Holdings

McKesson to Acquire 80% Stake in PRISM Vision Holdings for $850 Million
After the purchase concludes, the firm intends to include PRISM Vision into its U.S. Pharmaceutical division subject to further regulations and other requirements. According to McKesson, the deal fits its approach of increasing its footprint in ophthalmology and community-based specialty care.
McKesson Stock May Rise With PRISM Vision Holdings Acquisition
McKesson Corporation MCK recently announced that it has signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a premier provider of general ophthalmology and retina management services,
McKesson to acquire majority stake in PRISM Vision for $850M
IRVING, Texas - McKesson Corporation (NYSE: NYSE:MCK), a $76 billion healthcare giant with "GREAT" financial health according to InvestingPro metrics, has entered into a definitive agreement to acquire an 80% stake in PRISM Vision Holdings,
McKesson To Acquire Controlling Interest In PRISM Vision - Quick Facts
McKesson (MCK) signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC, a provider of general
Eyeing Ophthalmology in $850M Deal, Irving’s McKesson To Snag Controlling Interest in PRISM Vision Holdings
McKesson said it will acquire an 80% interest in the provider of general ophthalmology and retina management services. PRISM Vision physicians will continue to retain a 20% interest in their company.
McKesson to buy controlling stake in eye services organization for $850M
Irving-based McKesson (NYSE: MCK) announced on Feb. 4 an agreement to buy an 80% controlling interest in New Providence, New Jersey-based Prism Vision Holdings LLC from private equity firm Quad-C Management Inc. Physicians will retain a 20% interest in the organization, which does business as Prism Vision Group.
McKesson Acquires 80% Stake in PRISM Vision Holdings for $850M
McKesson expects PRISM Vision to add about 20 cents to 30 cents to its adjusted earnings per share in the first 12 months following the close of the transaction, and then to be between 65 cents and 75 cents accretive by the end of the third year.
McKesson to acquire controlling stake in Prism Vision for $850M, sees accretion
McKesson (MCK) announced that it signed a definitive agreement to acquire a controlling interest in Prism Vision. McKesson will purchase an 80%
McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings, LLC
McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a premier provider of general ophthalmology and retina management services,
McKesson acquires majority stake in Prism Vision in $850M deal
McKesson Corporation has signed a definitive agreement to acquire an 80% stake in Prism Vision Holdings from Quad-C for approximately $850 million.
McKesson to take 80% interest in PRISM Vision for about $850M
McKesson (NYSE:MCK) has agreed to acquire an 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, from Quad-C for about $850M. PRISM Vision physicians will continue to retain a 20% interest in PRISM Vision.
McKesson to Acquire Eye-Care Platform; Posts Higher 3Q Revenue, Profit
McKesson inked a deal to buy a controlling interest in Prism Vision Holdings, as it also logged higher profit and revenue in its fiscal third quarter. The drug distributor said Wednesday that it ...
McKesson Corp (MCK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
McKesson Corp (MCK) reports an 18% revenue increase and raises EPS guidance amid strategic investments and acquisitions.